专利号:US-5578500-A 优先权日:1991-07-31 标 题 :Reagents and methods for the quantification of imipramine or desipramine in biological fluids 发明人:ADAMCZYK MACIEJ; HARRINGTON CHARLES A; JOHNSON DONALD 权利人:ABBOTT LAB 摘要:Immunoassay methods and reagents for the specific quantification of imipramine or desipramine in a test sample are disclosed. The measurement of imipramine or desipramine is accomplished in a specific immunoassay employing antibodies prepared with imipramine or desipramine derivatives of the Formula III: ##STR1## wherein P is an immunogenic carrier material, X is two heteroatoms, Y is a linking group comprising from 1 to 6 carbon atoms and P is an immunogenic carrier material, and wherein for imipramine, R is CH 3 , and for desipramine, R is H. n The present invention also describes the synthesis of unique labeled reagents of the structure of the Formula IV: ##STR2## wherein Z is a linking group comprising 1 to 4 carbon atoms and 0 to 2 heteroatoms and Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and wherein for imipramine, R 1 is CH 3 , and for desipramine, R 1 is H.
专利号:GB-2291819-A 优先权日:1991-06-19 标题 :Process for the synthesis of hydrocarbons from synthesis gases in the presence of a cobalt-based catalyst
专利号:CA-3223733-A1 优先权日:2021-07-13 标题:A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester
专利号:US-11459325-B2 优先权日:2018-01-31 标题:Heterocyclic compound 发明人:TANAKA YUTA; OHASHI TOMOHIRO; IKEDA ZENICHI; TANAKA YUTA; PÜNNER FLORIAN; YAMAMOTO TAKESHI; KAKEGAWA KEIKO; KIKUCHI FUMIAKI; MORISHITA NAO; KASAHARA TAKAHITO; SETO MASAKI; NAKAMURA MINORU; TAKAMI KAZUAKI; MURAKAMI MASATAKA; DAINI MASAKI; MIKAMI SATOSHI; SASAKI MINORU 权利人:TAKEDA PHARMACEUTICALS CO 摘要:The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. n The present invention relates to a compound represented by the formula (I): n nwherein each symbol is as described in the specification, or a salt thereof.
专利号:US-2009028948-A1 优先权日:2004-12-31 标 题 :Nanoparticle composition and methods of synthesis thereof
专利号:US-2014315720-A1 优先权日:2012-10-24 标 题 :Polysaccharide ester microspheres and methods and articles relating thereto 发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY 权利人:CELANESE ACETATE LLC 摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
1: Bellows BK, Nelson RE, Oderda GM, LaFleur J. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine. Pain. 2016 Jan;157(1):203-13. doi: 10.1097/j.pain.0000000000000350. doi: 10.1016/j.ejphar.2014.02.012. Epub 2014 Feb 20. doi: 10.1055/s-0034-1377041. Epub 2014 Jun 23. doi: 10.1016/j.pnpbp.2016.05.002. Epub 2016 May 12. doi: 10.1016/S0140-6736(16)30385-3. Epub 2016 Jun 8. doi: 10.14348/molcells.2015.0131. Epub 2015 Aug 4. 8: Chau DT, Khokhar JY, Gulick D, Dawson R, Green AI. Desipramine enhances the ability of paliperidone to decrease alcohol drinking. J Psychiatr Res. 2015 Oct;69:9-18. doi: 10.1016/j.jpsychires.2015.07.010. Epub 2015 Jul 18. 9: Hasebe S, Ago Y, Nishiyama S, Oka S, Hashimoto H, Takuma K, Matsuda T. Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice. Behav Pharmacol. 2015 Oct;26(7 Spec No):681-90. doi: 10.1097/FBP.0000000000000140. doi: 10.1016/j.brainresbull.2011.09.014. Epub 2011 Sep 24. doi: 10.1016/j.scitotenv.2015.05.135. Epub 2015 Jun 8.
合成参考文献
参考文献:10.1007/s00213-011-2405-2 摘要:Pattij T, Schetters D, Schoffelmeer AN, van Gaalen MM. On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists. Psychopharmacology (Berl). 2012 Jan;219(2):327–40.